BAY 2666605

SKU: orb1297869

Description

BAY 2666605 is a potent, orally bioavailable dual inhibitor of PDE3A (IC50=87 nM) and PDE3B (IC50=50 nM). This research compound exhibits anticancer activity and is utilized in preclinical studies to investigate PDE3 signaling in cellular proliferation and tumor models.

Research Area

Metabolism Research

Key Properties

• CAS Number: 2275774-60-0
• MW: 352.28
• Purity: 99.98% (May vary between batches)
• Formula: C₁₇H₁₂F₄N₂O₂
• SMILES: C[C@@H]1OC(=O)NN=C1c1ccc(-c2ccc(F)cc2)c(c1)C(F)(F)F
• Target: PDE
• Solubility: DMSO:245 mg/mL (695.47 mM)

Bioactivity

• Target IC50:
  PDE3B:50 nM|PDE3A:87 nM
• In Vivo:
  In murine xenotransplantation models of human cancer, BAY 2666605 (5 mg/kg; p.o) exhibits anti-tumor efficacy.
• In Vitro:
  BAY 2666605 inhibits brain cancer(glioma, more specifically glioblastoma, astrocytoma), breast cancer (ductal carcinoma and adenocarcinoma), cervical cancer, AML(erythroleukemia), lung cancer(NSCLC adenocarcinoma and SCLC), skin cancer(melanoma), esophagus cancer (squamous cell carcinoma), ovarian cancer, (teratocarcinoma, adenocarcinoma), pancreas cancer and prostatic cancer.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Phosphodiesterase (PDE), Inhibitor, inhibit, PDE3A, PDE3A-SLFN12 Complex, PDE3B, orally active, BAY2666605, BAY-2666605, BAY 2666605, anticancer effect

Compound Identifiers

PubChem CID

137465182